Normal view
-
cs.AI, q-bio.NC updates on arXiv.org
-
Three Creates All: You Only Sample 3 Steps
arXiv:2603.22375v1 Announce Type: cross Abstract: Diffusion models deliver high-fidelity generation but remain slow at inference time due to many sequential network evaluations. We find that standard timestep conditioning becomes a key bottleneck for few-step sampling. Motivated by layer-dependent denoising dynamics, we propose Multi-layer Time Embedding Optimization (MTEO), which freeze the pretrained diffusion backbone and distill a small set of step-wise, layer-wise time embeddings from refe
-
cs.AI, q-bio.NC updates on arXiv.org
-
From Context to Intent: Reasoning-Guided Function-Level Code Completion
arXiv:2508.09537v2 Announce Type: replace-cross Abstract: The growing capabilities of Large Language Models (LLMs) have led to their widespread adoption for function completion within code repositories. Recent studies on such tasks show promising results when explicit instructions, often in the form of docstrings, are available to guide the completion. However, in real-world scenarios, clear docstrings are frequently absent. Under such conditions, LLMs typically fail to produce accurate complet
From Context to Intent: Reasoning-Guided Function-Level Code Completion
-
Omics in Hepatocellular
-
The dual regulatory role of METTL14-mediated m<sup>6</sup>A modification in tumorigenesis and its underlying mechanisms
Front Oncol. 2026 Mar 4;16:1771313. doi: 10.3389/fonc.2026.1771313. eCollection 2026.ABSTRACTN6-methyladenosine (m6A), as the most abundant RNA epitranscriptional modification in eukaryotes, its key component of the methyltransferase complex, METTL14, not only cooperates in catalyzing m6A deposition but also has functions independent of methyltransferase activity. This article systematically reviews the dual regulatory role of METTL14 in tumors and its molecular mechanisms, mainly organizing the
The dual regulatory role of METTL14-mediated m<sup>6</sup>A modification in tumorigenesis and its underlying mechanisms
Front Oncol. 2026 Mar 4;16:1771313. doi: 10.3389/fonc.2026.1771313. eCollection 2026.
ABSTRACT
N6-methyladenosine (m6A), as the most abundant RNA epitranscriptional modification in eukaryotes, its key component of the methyltransferase complex, METTL14, not only cooperates in catalyzing m6A deposition but also has functions independent of methyltransferase activity. This article systematically reviews the dual regulatory role of METTL14 in tumors and its molecular mechanisms, mainly organizing the relevant research in a logical sequence of "tumor suppressive effect - tumor promoting effect - controversial or context-dependent". Studies have shown that METTL14 often plays a tumor suppressive role in tumors such as hepatocellular carcinoma and colorectal cancer, while in pancreatic cancer and nasopharyngeal carcinoma, it mostly promotes malignant progression, showing a high degree of context dependence. This article focuses on two key mechanisms: on the one hand, METTL14 precisely regulates the processing, stability, and function of non-coding RNAs (including miRNAs, lncRNAs, and circRNAs) through m6A modification, reshaping the competitive endogenous RNA (ceRNA) network; on the other hand, it shapes an immunosuppressive tumor microenvironment by directly upregulating immune checkpoints such as PD-L1, mediating metabolism-immune interactions, and regulating the function of immune cells. Its functional duality also stems from the selective regulation of key pathways such as PI3K/AKT, as well as the differential interpretation by different m6A readers (such as YTHDF2 and IGF2BPs). Given the close association of these mechanisms with clinical prognosis, the expression level of METTL14 shows significant potential as a prognostic marker and therapeutic target; in the future, it is necessary to combine single-cell multi-omics and other technologies to analyze its dynamic regulatory network in specific tumor contexts and explore precise treatment strategies based on synthetic lethality or targeting downstream effector molecules.
PMID:41858346 | PMC:PMC12995618 | DOI:10.3389/fonc.2026.1771313
-
Omics in Hepatocellular
-
Multi-omics analysis and experimental validation uncovers prognosis significance of IKBIP in patients with hepatocellular carcinoma: a multicenter cohort study
BMC Gastroenterol. 2026 Mar 19. doi: 10.1186/s12876-026-04756-y. Online ahead of print.NO ABSTRACTPMID:41851828 | DOI:10.1186/s12876-026-04756-y
Multi-omics analysis and experimental validation uncovers prognosis significance of IKBIP in patients with hepatocellular carcinoma: a multicenter cohort study
BMC Gastroenterol. 2026 Mar 19. doi: 10.1186/s12876-026-04756-y. Online ahead of print.
NO ABSTRACT
PMID:41851828 | DOI:10.1186/s12876-026-04756-y